TABLE 2.
Efficacy of cadazolid and vancomycin in the mouse model of CDAD
| Compound (no. of pooled studies) | % survival (total no. of mice tested)a |
|||||||
|---|---|---|---|---|---|---|---|---|
| During treatment phase, day 5 postinfection |
Posttreatment phase, day 18 postinfection |
|||||||
| Vehicle control | Drug dose (mg/kg) |
Vehicle control | Drug dose (mg/kg) |
|||||
| 0.1 | 1 | 10 | 0.1 | 1 | 10 | |||
| Cadazolid (all)b | 17.5 (137) | 46.7 (107) | 96.5 (114) | 100 (107) | 12.4 (137) | 40.2 (107) | 92.1 (114) | 87.9 (107) |
| Cadazolid (3)c | 11 (18) | 9.1 (11) | 76 (17) | 100 (11) | 5.6 (18) | 9.1 (11) | 70.5 (17) | 91 (11) |
| Vancomycin (3)c | 12.5 (16) | 9.1 (11) | 88 (17) | 100 (11) | 12.5 (16) | 9.1 (11) | 70.5 (17) | 82 (11) |
a
Mice (n = 5 to 7 per group) were treated for 4 days once daily.
b
Pooled data of all studies with cadazolid compared to vehicle (n = 17).
c
Pooled data of 3 studies with side-to-side comparison of cadazolid and vancomycin.